Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent

Table 4

Outcomes in patients with PC from CRC treated with CRS and HIPEC or Early Postoperative Intraperitoneal Chemotherapy.

Study	Year	No of patients	Perfusion agent, dose, length, t°	Median OS (months),; (resection status)
Glehen et al. [10]	2004	53; 23	MMC: 40-60 mg at 46-48°C for 90 min	13 (all patients); 33 (CC-0)
Glehen et al. [11]	2004	506; 271; 106	(1) MMC (30/50 mg/m^2) ± cisplatin (50-100 mg/m^2) at 41-42.5 °C for 60-120 min; (2) oxaliplatin (360-460 mg/m^2) ± irinoteacan (100-200 mg/m^2) ± IV 5-FU + leucovorin at 43 °C for 30 min	19 (all patients); 32 (CC-0); 24 (CC-1)
Elias et al. [12]	2010	523; 439	(1) MMC (30/50 mg/m^2) ± cisplatin (50-100 mg/m^2) at 41°C for 60-120 min; (2) oxaliplatin (360-460 mg/m^2) ± irinoteacan (200 mg/m^2) ± IV 5-FU + leucovorin at 43 °C for 30 min	30 (all patients); 33 (CC-0)
Verwaal et al. [13]	2008	54	MMC: initial dose of 17.5 mg/m^2 with additional 8.8 mg/m^2 every 30 min (maximal dose in total 70 mg/m^2)at 41-42 °C for 90 min	22 (all patients); 48 (R-1)
Franko et al. [14]	2010	67	MMC: initial dose of 30 mg for 60 min with additional 10 mg after for 40 min	35 (all patients)
ASPSM study [15]	2014	392	MMC: initial dose of 30 mg with additional 10 mg in 60 min at 42°C for 90 minutes	33 (CC-0/1)
This study	2018	19; 29	Melphalan; MMC	36 (CC-0/1); 28 (CC-0/1)

MMC: mitomycin-C; OS: overall survival; R-0: no gross disease with negative resection margins, R-1: no gross disease with positive resection margins; CC-0: no visible residual disease; CC-1: residual disease <2mm;